These findings suggested that chemerin promotes gastric cancer cell invasion partly by suppressing TIMP-1 and TIMP-2, highlighting the potential role of chemerin receptor antagonists as therapeutic agents to inhibit gastric cancer progression. This evidence concerns the gene TIMP2 and gastric cancer.